Radiosurgery is a genuinely good option when high-quality total surgical removal isn't achievable. But when a tumor can be safely and completely removed by an experienced surgical team, surgery still offers something radiosurgery cannot: the tumor is actually gone, not just stopped from growing. In other words, a good surgical outcome tends to outperform radiosurgery, while a poor one tends to make radiosurgery the better choice, so the right recommendation depends heavily on the surgical outcome that can realistically be expected.
An acoustic neuroma, more precisely called a vestibular schwannoma, is a benign (WHO Grade 1) tumor that grows from the Schwann cells covering the vestibular branch of the 8th cranial nerve, the nerve responsible for hearing and balance. It develops in the cerebellopontine angle, the space between the brainstem and cerebellum, often extending into the internal auditory canal. It's the most common tumor found in this location and the most common intracranial schwannoma in adults.
These tumors grow slowly, typically 1-10 mm per year, and malignant transformation is essentially never seen. About 95% of cases are sporadic and affect only one side. Bilateral acoustic neuromas are strongly associated with Neurofibromatosis Type 2 (NF2), a genetic condition that changes both the surgical approach and the expected outcome.
Several classification systems are used to describe these tumors (Yaşargil, Samii, Koos, Sekhar, among others), based on either size or how far the tumor extends toward the brainstem. The Samii classification, which grades tumors by extent rather than size alone, is shown below.
The first symptom is almost always gradual, one-sided hearing loss, though it's occasionally sudden. As the tumor grows, other symptoms can follow.
Contrast-enhanced MRI is the gold standard, typically showing a well-defined, often intensely and homogeneously enhancing mass at the cerebellopontine angle with a characteristic extension into the internal auditory canal. A hearing test (audiogram) establishes a baseline and is tracked over time using the Gardner-Robertson scale. Facial nerve function is assessed before surgery and monitored afterward using the House-Brackmann scale.
Three strategies are used in the management of acoustic neuroma: observation with serial MRI, microsurgical removal, and stereotactic radiosurgery (SRS). The right choice depends on tumor size and growth rate, the patient's age and general health, hearing status, and whether brainstem compression is present, and it's typically reached through a multidisciplinary approach involving neurosurgery and radiation oncology together.
Surgical removal can be used for tumors of any size, though hearing and facial nerve preservation are best achieved in smaller tumors. During surgery, intraoperative nerve monitoring continuously tracks facial nerve function, allowing the surgical team to recognize and protect the nerve before injury occurs. Large tumors, particularly those compressing the brainstem, generally require surgery; when the facial nerve is at high risk, a planned subtotal removal followed by radiosurgery to the remaining tumor is a widely accepted modern approach.
Stereotactic radiosurgery (delivered with platforms such as Gamma Knife, CyberKnife, or LINAC-based systems) is highly effective for tumors under 3 cm, with the goal of halting growth rather than removing the tumor; it's less effective in NF2-related disease.
Observation is a reasonable option for small tumors in older patients or those with minimal symptoms, given how slowly these tumors typically grow.
Explore how the decision is made for acoustic neuroma, and what a typical treatment course looks like.
Contrast-enhanced MRI defines the tumor's size and extent; an audiogram and facial nerve exam establish a baseline.
Tumor size and growth rate, the patient's age and general health, hearing status, and any brainstem compression are weighed together. The multidisciplinary team then reaches a joint recommendation, the options and details are discussed with the patient, and the final decision is made together.
From here, the right path depends mainly on tumor size and behavior over time. Tap a profile to see more.
Regular MRI and hearing evaluations confirm the tumor remains controlled over the long term.
Imaging, audiogram, facial nerve baseline exam, and anesthesia clearance. The surgical approach, retrosigmoid, translabyrinthine, or middle fossa, is chosen based on tumor size and hearing status.
Microsurgical removal is carried out with continuous facial nerve monitoring to protect nerve function. An early MRI is obtained that same night to confirm the extent of removal. Larger tumors or cases with significant brainstem compression warrant a night of ICU observation afterward for close monitoring.
Patients who spent the first night in the ICU are transferred to the regular ward. Neurological exam, initial assessment of facial nerve function, and gradual mobilization.
Patients with a stable neurological exam and no signs of a CSF leak are discharged with instructions.
Facial nerve function is graded using the House-Brackmann scale. Any temporary weakness at this stage tends to improve over the following weeks to months. Patients cleared at this visit typically return to their home country.
A further control MRI is obtained for long-term monitoring. If a planned subtotal removal was performed, radiosurgery to the remaining tumor is scheduled at this stage.
Shown for a typical, uncomplicated case. Individual treatment course may vary.